Prostate and other male cancers:
Indications for: ETOPOPHOS
In combination with other chemotherapeutic drugs for refractory testicular tumors.
Adult Dosage:
Give by IV infusion over 5 to 210 minutes. 50–100mg/m2 per day on Days 1 through 5 or 100mg/m2 per day on Days 1, 3, 5 of each 21-day (or 28-day) cycle. Renal impairment (CrCl 15–50mL/min): reduce to 75% of dose; (<15mL/min): consider further dose reduction.
Children Dosage:
Not established.
ETOPOPHOS Warnings/Precautions:
Monitor CBCs before each cycle and as clinically indicated. Embryo-fetal toxicity. Advise use of effective contraception during therapy and for 6 months (females) or 4 months (males w. female partners) after final dose. Pregnancy, nursing mothers: not recommended.
ETOPOPHOS Classification:
Topoisomerase inhibitor.
ETOPOPHOS Interactions:
May potentiate warfarin; monitor INR. May be potentiated by cisplatin. May be antagonized by antiepileptics (eg, phenytoin, phenobarbital, carbamazepine, valproic acid).
Adverse Reactions:
Myelosuppression (esp. neutropenia, thrombocytopenia), nausea, vomiting, abdominal pain, constipation, dysphagia, fever, infections, ocular disorders, interstitial pneumonitis, pulmonary fibrosis, skin reactions, seizure, hepatotoxicity; secondary leukemias, hypersensitivity reactions (permanently discontinue if severe reaction occurs), infertility, others.
How Supplied:
Single-dose vials—1
Respiratory and thoracic cancers:
Indications for: ETOPOPHOS
In combination with cisplatin for small cell lung cancer.
Adult Dosage:
Give by IV infusion over 5 to 210 minutes. 35mg/m2 per day for 4 days or 50mg/m2 per day for 5 days. Renal impairment (CrCl 15–50mL/min): reduce to 75% of dose; (<15mL/min): consider further dose reduction.
Children Dosage:
Not established.
ETOPOPHOS Warnings/Precautions:
Monitor CBCs before each cycle and as clinically indicated. Embryo-fetal toxicity. Advise use of effective contraception during therapy and for 6 months (females) or 4 months (males w. female partners) after final dose. Pregnancy, nursing mothers: not recommended.
ETOPOPHOS Classification:
Topoisomerase inhibitor.
ETOPOPHOS Interactions:
May potentiate warfarin; monitor INR. May be potentiated by cisplatin. May be antagonized by antiepileptics (eg, phenytoin, phenobarbital, carbamazepine, valproic acid).
Adverse Reactions:
Myelosuppression (esp. neutropenia, thrombocytopenia), nausea, vomiting, abdominal pain, constipation, dysphagia, fever, infections, ocular disorders, interstitial pneumonitis, pulmonary fibrosis, skin reactions, seizure, hepatotoxicity; secondary leukemias, hypersensitivity reactions (permanently discontinue if severe reaction occurs), infertility, others.
How Supplied:
Single-dose vials—1
